263 related articles for article (PubMed ID: 12970769)
1. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors.
Dewar AL; Domaschenz RM; Doherty KV; Hughes TP; Lyons AB
Leukemia; 2003 Sep; 17(9):1713-21. PubMed ID: 12970769
[TBL] [Abstract][Full Text] [Related]
2. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance.
Taylor JR; Brownlow N; Domin J; Dibb NJ
Oncogene; 2006 Jan; 25(1):147-51. PubMed ID: 16170366
[TBL] [Abstract][Full Text] [Related]
3. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.
Dewar AL; Cambareri AC; Zannettino AC; Miller BL; Doherty KV; Hughes TP; Lyons AB
Blood; 2005 Apr; 105(8):3127-32. PubMed ID: 15637141
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor.
Pierce A; Spooncer E; Ainsworth S; Whetton AD
Oncogene; 2002 May; 21(19):3068-75. PubMed ID: 12082538
[TBL] [Abstract][Full Text] [Related]
5. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.
Wang WL; Healy ME; Sattler M; Verma S; Lin J; Maulik G; Stiles CD; Griffin JD; Johnson BE; Salgia R
Oncogene; 2000 Jul; 19(31):3521-8. PubMed ID: 10918610
[TBL] [Abstract][Full Text] [Related]
7. Nonproliferating CML CD34+ progenitors are resistant to apoptosis induced by a wide range of proapoptotic stimuli.
Holtz MS; Forman SJ; Bhatia R
Leukemia; 2005 Jun; 19(6):1034-41. PubMed ID: 15815728
[TBL] [Abstract][Full Text] [Related]
8. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors.
Buchdunger E; Cioffi CL; Law N; Stover D; Ohno-Jones S; Druker BJ; Lydon NB
J Pharmacol Exp Ther; 2000 Oct; 295(1):139-45. PubMed ID: 10991971
[TBL] [Abstract][Full Text] [Related]
9. Effect of mutational inactivation of tyrosine kinase activity on BCR/ABL-induced abnormalities in cell growth and adhesion in human hematopoietic progenitors.
Ramaraj P; Singh H; Niu N; Chu S; Holtz M; Yee JK; Bhatia R
Cancer Res; 2004 Aug; 64(15):5322-31. PubMed ID: 15289338
[TBL] [Abstract][Full Text] [Related]
10. Bone marrow angiotensin AT1 receptor regulates differentiation of monocyte lineage progenitors from hematopoietic stem cells.
Tsubakimoto Y; Yamada H; Yokoi H; Kishida S; Takata H; Kawahito H; Matsui A; Urao N; Nozawa Y; Hirai H; Imanishi J; Ashihara E; Maekawa T; Takahashi T; Okigaki M; Matsubara H
Arterioscler Thromb Vasc Biol; 2009 Oct; 29(10):1529-36. PubMed ID: 19628784
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate minimally affects bcr-abl+ and normal monocyte-derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell-T cell activation.
Boissel N; Rousselot P; Raffoux E; Cayuela JM; Soulier J; Mooney N; Charron D; Dombret H; Toubert A; Rea D
J Leukoc Biol; 2006 Apr; 79(4):747-56. PubMed ID: 16461746
[TBL] [Abstract][Full Text] [Related]
12. c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis.
Paniagua RT; Chang A; Mariano MM; Stein EA; Wang Q; Lindstrom TM; Sharpe O; Roscow C; Ho PP; Lee DM; Robinson WH
Arthritis Res Ther; 2010; 12(1):R32. PubMed ID: 20181277
[TBL] [Abstract][Full Text] [Related]
13. In vitro induction of inhibitory macrophage differentiation by granulocyte-macrophage colony-stimulating factor, stem cell factor and interferon-gamma from lineage phenotypes-negative c-kit-positive murine hematopoietic progenitor cells.
Ferret-Bernard S; Saï P; Bach JM
Immunol Lett; 2004 Feb; 91(2-3):221-7. PubMed ID: 15019293
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the activity of a human granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein (pIXY 321) by the macrocyclic lactone protein kinase C activator bryostatin 1.
McCrady CW; Li F; Pettit GR; Grant S
Exp Hematol; 1993 Jul; 21(7):893-900. PubMed ID: 7686503
[TBL] [Abstract][Full Text] [Related]
15. Effect of tyrosine kinase inhibition using imatinib on normal lymphohematopoietic cells.
Balabanov S; Appel S; Kanz L; Brossart P; Brümmendorf TH
Ann N Y Acad Sci; 2005 Jun; 1044():168-77. PubMed ID: 15958710
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
17. Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow.
Reid CD; Stackpoole A; Meager A; Tikerpae J
J Immunol; 1992 Oct; 149(8):2681-8. PubMed ID: 1383322
[TBL] [Abstract][Full Text] [Related]
18. PHA-680626 exhibits anti-proliferative and pro-apoptotic activity on Imatinib-resistant chronic myeloid leukemia cell lines and primary CD34+ cells by inhibition of both Bcr-Abl tyrosine kinase and Aurora kinases.
Gontarewicz A; Balabanov S; Keller G; Panse J; Schafhausen P; Bokemeyer C; Fiedler W; Moll J; Brümmendorf TH
Leuk Res; 2008 Dec; 32(12):1857-65. PubMed ID: 18514829
[TBL] [Abstract][Full Text] [Related]
19. Erythropoietin overcomes imatinib-induced apoptosis and induces erythroid differentiation in TF-1/bcr-abl cells.
Uchida M; Watanabe T; Kunitama M; Mori M; Kikuchi S; Yoshida K; Kirito K; Nagai T; Ozawa K; Komatsu N
Stem Cells; 2004; 22(4):609-16. PubMed ID: 15277706
[TBL] [Abstract][Full Text] [Related]
20. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
